Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trialsGary Lichtenstein, William J. Sandborn, Colleen Marano et al.|Alimentary Pharmacology & Therapeutics|2009Cited by 195
Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 trialWJ Sandborn, J F Colombel, WJS de Villiers et al.|Zeitschrift für Gastroenterologie|2005Cited by 51
Monocyte chemoattractant protein 1 (MCP-1) in temporal arteritis and polymyalgia rheumaticaTorkell Ellingsen, Kristian Stengaard‐Pedersen, A. Olson et al.|Annals of the Rheumatic Diseases|2000Cited by 36
Infliximab Induces and Maintains Mucosal Healing in Ulcerative Colitis PatientsWilliam J. Sandborn, P. Rutgeerts, Jean‐Frédéric Colombel et al.|The American Journal of Gastroenterology|2005Cited by 5
Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Analysis from ACT 1 and ACT 2William J. Sandborn, J F Colombel, P. Rutgeerts et al.|The American Journal of Gastroenterology|2007Cited by 2